Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

@article{NezNateras2014PredictingRT,
  title={Predicting response to bacillus Calmette-Gu{\'e}rin (BCG) in patients with carcinoma in situ of the bladder.},
  author={Rafael Alejandro N{\'u}{\~n}ez-Nateras and Erik Peter Castle and Cheryl A. Protheroe and Melissa L. Stanton and Tolgay I Ocal and Erin N. Ferrigni and Sergei I. Ochkur and Elizabeth A. Jacobsen and Yue-xian Hou and Paul E. Andrews and Thomas Vail Colby and Nancy A. Lee and James Joseph Lee},
  journal={Urologic oncology},
  year={2014},
  volume={32 1},
  pages={45.e23-30}
}
PURPOSE Currently, there is no reliable tool to predict response to intravesical bacillus Calmette-Guérin (BCG). Based on the fact that BCG is a Th1-polarizing immunotherapy, we attempt to correlate the pretreatment immunologic tumor microenvironment (Th1 or Th2) with response to therapy. MATERIALS AND METHODS Bladder cancer patients with initial diagnosis of carcinoma in situ (Tis) were stratified based on their response to BCG treatment. A total of 38 patients met inclusion criteria (20… CONTINUE READING
Highly Cited
This paper has 29 citations. REVIEW CITATIONS
11 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Similar Papers

Loading similar papers…